Difference between revisions of "ROS1-rearranged non-small cell lung carcinoma"

From Libre Pathology
Jump to navigation Jump to search
 
(10 intermediate revisions by the same user not shown)
Line 1: Line 1:
[[Image:Adenocarcinoma_-_ROS1_positive_-_ROS1_--_high_mag.jpg|thumb|right|[[Micrograph]] showing a ROS1-positive [[adenocarcinoma of the lung]]. ROS1 [[immunostain]].]]
'''ROS1-rearranged non-small cell lung carcinoma''' is a subtype of [[non-small cell lung carcinoma]] that can be treated with [[ALK inhibitors]].<ref name=pmid25264305>{{Cite journal  | last1 = Shaw | first1 = AT. | last2 = Ou | first2 = SH. | last3 = Bang | first3 = YJ. | last4 = Camidge | first4 = DR. | last5 = Solomon | first5 = BJ. | last6 = Salgia | first6 = R. | last7 = Riely | first7 = GJ. | last8 = Varella-Garcia | first8 = M. | last9 = Shapiro | first9 = GI. | title = Crizotinib in ROS1-rearranged non-small-cell lung cancer. | journal = N Engl J Med | volume = 371 | issue = 21 | pages = 1963-71 | month = Nov | year = 2014 | doi = 10.1056/NEJMoa1406766 | PMID = 25264305 }}</ref>
'''ROS1-rearranged non-small cell lung carcinoma''' is a subtype of [[non-small cell lung carcinoma]] that can be treated with [[ALK inhibitors]].<ref name=pmid25264305>{{Cite journal  | last1 = Shaw | first1 = AT. | last2 = Ou | first2 = SH. | last3 = Bang | first3 = YJ. | last4 = Camidge | first4 = DR. | last5 = Solomon | first5 = BJ. | last6 = Salgia | first6 = R. | last7 = Riely | first7 = GJ. | last8 = Varella-Garcia | first8 = M. | last9 = Shapiro | first9 = GI. | title = Crizotinib in ROS1-rearranged non-small-cell lung cancer. | journal = N Engl J Med | volume = 371 | issue = 21 | pages = 1963-71 | month = Nov | year = 2014 | doi = 10.1056/NEJMoa1406766 | PMID = 25264305 }}</ref>


==General==
==General==
*ROS1-rearrangements are seen in approximately 1-2% of [[non-small cell carcinoma]].<ref name=pmid31720561>{{cite journal |vauthors=Patil T, Simons E, Mushtaq R, Pacheco JM, Doebele RC, Bowles DW |title=Targeted therapies for ROS1-rearranged non-small cell lung cancer |journal=Drugs Today |volume=55 |issue=10 |pages=641–652 |date=October 2019 |pmid=31720561 |doi=10.1358/dot.2019.55.10.3030646 |url=}}</ref>
*ROS1-rearrangements are seen in approximately 1-2% of [[non-small cell carcinoma]].<ref name=pmid31720561>{{cite journal |authors=Patil T, Simons E, Mushtaq R, Pacheco JM, Doebele RC, Bowles DW |title=Targeted therapies for ROS1-rearranged non-small cell lung cancer |journal=Drugs Today |volume=55 |issue=10 |pages=641–652 |date=October 2019 |pmid=31720561 |doi=10.1358/dot.2019.55.10.3030646 |url=}}</ref>
*Respond to target therapy, e.g. [[crizotinib]].<ref name=pmid30980071>{{cite journal |vauthors=Shaw AT, Riely GJ, Bang YJ, Kim DW, Camidge DR, Solomon BJ, Varella-Garcia M, Iafrate AJ, Shapiro GI, Usari T, Wang SC, Wilner KD, Clark JW, Ou SI |title=Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001 |journal=Ann. Oncol. |volume=30 |issue=7 |pages=1121–1126 |date=July 2019 |pmid=30980071 |pmc=6637370 |doi=10.1093/annonc/mdz131 |url=}}</ref>
*Respond to targeted therapy, e.g. [[crizotinib]].<ref name=pmid30980071>{{cite journal |authors=Shaw AT, Riely GJ, Bang YJ, Kim DW, Camidge DR, Solomon BJ, Varella-Garcia M, Iafrate AJ, Shapiro GI, Usari T, Wang SC, Wilner KD, Clark JW, Ou SI |title=Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001 |journal=Ann. Oncol. |volume=30 |issue=7 |pages=1121–1126 |date=July 2019 |pmid=30980071 |pmc=6637370 |doi=10.1093/annonc/mdz131 |url=}}</ref>


==Microscopic==
==Microscopic==
Features:
Features:
*Histology not definitive; however, predictive features are:<ref name=pmid27648828/>  
*Histology not definitive; however, predictive features are:<ref name=pmid27648828/>  
**Cribriform structure.
**[[Cribriform structure]].
**[[Psammoma bodies]]
**[[Psammoma bodies]]


Note:
Note:
*Most common pattern varies by specimen type:<ref name=pmid27648828>{{cite journal |vauthors=Zhou J, Zhao J, Zheng J, Kong M, Sun K, Wang B, Chen X, Ding W, Zhou J |title=A Prediction Model for ROS1-Rearranged Lung Adenocarcinomas based on Histologic Features |journal=PLoS ONE |volume=11 |issue=9 |pages=e0161861 |date=2016 |pmid=27648828 |pmc=5029801 |doi=10.1371/journal.pone.0161861 |url=}}</ref>
*Most common pattern varies by specimen type:<ref name=pmid27648828>{{cite journal |authors=Zhou J, Zhao J, Zheng J, Kong M, Sun K, Wang B, Chen X, Ding W, Zhou J |title=A Prediction Model for ROS1-Rearranged Lung Adenocarcinomas based on Histologic Features |journal=PLoS ONE |volume=11 |issue=9 |pages=e0161861 |date=2016 |pmid=27648828 |pmc=5029801 |doi=10.1371/journal.pone.0161861 |url=}}</ref>
**Biopsy specimens: solid pattern most common.
**Biopsy specimens: solid pattern most common.
**Resection specimens: acinar pattern most common.
**Resection specimens: acinar pattern most common.
===Images===
<gallery>
Image: Adenocarcinoma - ROS1 positive -- low mag.jpg | NSmCC - low mag.
Image: Adenocarcinoma - ROS1 positive -- intermed mag.jpg | NSmCC - intermed. mag.
Image: Adenocarcinoma - ROS1 positive -- high mag.jpg | NSmCC - high mag.
Image: Adenocarcinoma - ROS1 positive -- very high mag.jpg | NSmCC - very high mag.
Image: Adenocarcinoma - ROS1 positive - TTF1 -- high mag.jpg | NSmCC - TTF-1 - high mag.
Image: Adenocarcinoma - ROS1 positive - napsin A -- high mag.jpg | NSmCC - napsin A - high mag.
</gallery>
==IHC==
*ROS1 +ve.
===Images===
<gallery>
Image: Adenocarcinoma - ROS1 positive - ROS1 -- low mag.jpg | NSmCC - ROS1 - low mag.
Image: Adenocarcinoma - ROS1 positive - ROS1 -- intermed mag.jpg | NSmCC - ROS1 - intermed. mag.
Image: Adenocarcinoma - ROS1 positive - ROS1 -- high mag.jpg | NSmCC - ROS1 -high mag.
</gallery>
==Molecular==
*ROS1 rearrangements can be demonstrated with dual-colour break apart [[FISH]] probes.<ref name=pmid27535289>{{cite journal |authors=Bubendorf L, Büttner R, Al-Dayel F, Dietel M, Elmberger G, Kerr K, López-Ríos F, Marchetti A, Öz B, Pauwels P, Penault-Llorca F, Rossi G, Ryška A, Thunnissen E |title=Testing for ROS1 in non-small cell lung cancer: a review with recommendations |journal=Virchows Arch. |volume=469 |issue=5 |pages=489–503 |date=November 2016 |pmid=27535289 |pmc=5082594 |doi=10.1007/s00428-016-2000-3 |url=}}</ref>


==See also==
==See also==
Line 22: Line 48:


==References==
==References==
{{Reflist|1}}
{{Reflist|2}}


[[Category:Diagnosis]]
[[Category:Diagnosis]]
[[Category:Molecular pathology]]

Latest revision as of 20:25, 24 May 2020

Micrograph showing a ROS1-positive adenocarcinoma of the lung. ROS1 immunostain.

ROS1-rearranged non-small cell lung carcinoma is a subtype of non-small cell lung carcinoma that can be treated with ALK inhibitors.[1]

General

Microscopic

Features:

Note:

  • Most common pattern varies by specimen type:[4]
    • Biopsy specimens: solid pattern most common.
    • Resection specimens: acinar pattern most common.

Images

  • NSmCC - low mag.

  • NSmCC - intermed. mag.

  • NSmCC - high mag.

  • NSmCC - very high mag.

  • NSmCC - TTF-1 - high mag.

  • NSmCC - napsin A - high mag.

IHC

  • ROS1 +ve.

Images

  • NSmCC - ROS1 - low mag.

  • NSmCC - ROS1 - intermed. mag.

  • NSmCC - ROS1 -high mag.

Molecular

  • ROS1 rearrangements can be demonstrated with dual-colour break apart FISH probes.[5]

See also

References

  1. ↑ Shaw, AT.; Ou, SH.; Bang, YJ.; Camidge, DR.; Solomon, BJ.; Salgia, R.; Riely, GJ.; Varella-Garcia, M. et al. (Nov 2014). "Crizotinib in ROS1-rearranged non-small-cell lung cancer.". N Engl J Med 371 (21): 1963-71. doi:10.1056/NEJMoa1406766. PMID 25264305.
  2. ↑ Patil T, Simons E, Mushtaq R, Pacheco JM, Doebele RC, Bowles DW (October 2019). "Targeted therapies for ROS1-rearranged non-small cell lung cancer". Drugs Today 55 (10): 641–652. doi:10.1358/dot.2019.55.10.3030646. PMID 31720561.
  3. ↑ Shaw AT, Riely GJ, Bang YJ, Kim DW, Camidge DR, Solomon BJ, Varella-Garcia M, Iafrate AJ, Shapiro GI, Usari T, Wang SC, Wilner KD, Clark JW, Ou SI (July 2019). "Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001". Ann. Oncol. 30 (7): 1121–1126. doi:10.1093/annonc/mdz131. PMC 6637370. PMID 30980071. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6637370/.
  4. ↑ 4.0 4.1 Zhou J, Zhao J, Zheng J, Kong M, Sun K, Wang B, Chen X, Ding W, Zhou J (2016). "A Prediction Model for ROS1-Rearranged Lung Adenocarcinomas based on Histologic Features". PLoS ONE 11 (9): e0161861. doi:10.1371/journal.pone.0161861. PMC 5029801. PMID 27648828. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029801/.
  5. ↑ Bubendorf L, Büttner R, Al-Dayel F, Dietel M, Elmberger G, Kerr K, López-Ríos F, Marchetti A, Öz B, Pauwels P, Penault-Llorca F, Rossi G, Ryška A, Thunnissen E (November 2016). "Testing for ROS1 in non-small cell lung cancer: a review with recommendations". Virchows Arch. 469 (5): 489–503. doi:10.1007/s00428-016-2000-3. PMC 5082594. PMID 27535289. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5082594/.
Retrieved from "https://librepathology.org/w/index.php?title=ROS1-rearranged_non-small_cell_lung_carcinoma&oldid=50792"